Drug giant GSK spins out S.F.-based venture unit with $500M fund

From single assets to platform technologies and cancer to neurodegeneration, a more broadly funded SR One is looking to make as many as 20 investments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.